RoosterBio & Repligen Collaborate to Advance Scalable Exosome Bioprocessing

Portfolio company Rooster Bio recently announced it has selected Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, as a collaboration partner to advance scalable exosome bioprocessing. Rooster Bio’s goal in this collaboration is to deliver solutions for manufacturing of exosomes using scalable and low shear technologies that enable cost-effective commercialization of these advanced therapies.

There has been a growing demand in exosomes supply in recent years due to their emerging role as intercellular messengers and their therapeutic potential as targeted and natural drug delivery vehicles with high specificity and efficiency. The complexity and fragility of the exosomes, scalability, yield, and purity of production processes are challenges to meeting demand. The combination of Rooster Bio’s and Repligen’s scalable platforms are being advanced to overcome those challenges.it has selected Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, as a collaboration partner to advance scalable exosome bioprocessing.